Upsher-Smith Launches Generic Version of Lomotil® (Diphenoxylate Hydrochloride and Atropine Sulfate Tablets)
Maple Grove, MN – August 31, 2018 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the
launch of Diphenoxylate Hydrochloride and Atropine Sulfate Tablets, USP, 2.5 mg/0.025 mg. Upsher-Smith’s product is an AA-rated generic version of the branded product, Lomotil® (diphenoxylate hydrochloride and atropine sulfate tablets)*.
The diphenoxylate hydrochloride and atropine sulfate tablet market had U.S. sales of approximately $64 million for the 12 months ending May, 2018 according to IQVIA.
Product Information
| Product | Strength | NDC # | Package Size |
| Diphenoxylate Hydrochloride and Atropine Sulfate Tablets, USP | 2.5 mg/0.025 mg | 0832-0590-11 | Bottle of 100 |
| 0832-0590-10 | Bottle of 1,000 |
For questions about ordering, please call Upsher-Smith at 1-800-654-2299.
Diphenoxylate Hydrochloride and Atropine Sulfate Tablets, USP are classified as a Schedule V controlled substance. Please refer to the full Prescribing Information for Diphenoxylate Hydrochloride and Atropine Sulfate Tablets, USP at http://www.upsher- smith.com/wp-content/uploads/70035587-NA Diphenoxylate_HCl_and_Atropine_Sulfate- Tablet-Insert-Rev0218.pdf. You can also call 1-888-650-3789 to obtain a copy of the full Prescribing Information.
You are encouraged to report suspected adverse reactions to Upsher-Smith Laboratories, LLC at 1-855-899-9180 or to the FDA by visiting http://www.fda.gov/medwatch.
About Upsher-Smith
Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that strives to improve the health and lives of patients through an unwavering commitment to high-quality products and sustainable growth. Since 1919, we’ve brought specialty generics and other products to a wide array of customers, backed by our attentive level of service, our strong industry relationships, and our dedication to uninterrupted supply. As we approach our 100th year in business, we enter a new ambitious era that has been accelerated by our 2017 acquisition by Sawai Pharmaceutical Co., Ltd. With our new owner, we look to leverage each other for growth worldwide and embark on an exciting new chapter. Together, we seek to deliver the best value for our stakeholders, and most importantly, do more good for the patients we serve. For more information, visit upshersmithstg.wpengine.com.
* Lomotil is a registered trademark of G.D. Searle LLC
Contact: Elizabeth Likly
Kovak-Likly Communications
203-762-8833, elikly@klcpr.com